Brief: Moonlake Immunotherapeutics Says On June 27, Entered Into Underwriting Agreement To Issue, Sell 8,000,000 Class A Ordinary Shares
29/06/2023 22:18
June 29 (Reuters) - MoonLake Immunotherapeutics
MLTX.O :
* MOONLAKE IMMUNOTHERAPEUTICS- ON JUNE 27, ENTERED INTO
UNDERWRITING AGREEMENT TO ISSUE, SELL 8,000,000 CLASS A ORDINARY
SHARES
Source text for Eikon: ID:
Further company coverage: MLTX.O
((Reuters.Brief@thomsonreuters.com;))
Recent news on MoonLake Immunotherapeutics
See all newsMoonLake jumps as AbbVie's weak skin drug data eases competition fears
Brief: Moonlake Immunotherapeutics Files For Mixed Shelf Offering, Size Not Disclosed
MoonLake Immunotherapeutics reports results for the quarter ended June 30 - Earnings Summary
MoonLake's psoriatic arthritis drug meets key goals in late-stage trial (updated)
MoonLake's psoriatic arthritis drug meets key goals in late-stage trial